Detalles de la búsqueda
1.
Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data - the PULSE study.
BMC Cardiovasc Disord
; 23(1): 374, 2023 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37495953
2.
Comorbidities and relevant outcomes, commonly associated with cancer, of patients newly diagnosed with advanced non-small-cell lung cancer in Sweden.
Eur J Cancer Care (Engl)
; 29(1): e13171, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31578054
3.
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Future Oncol
; 14(15): 1477-1486, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29376400
4.
Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
ESC Heart Fail
; 11(1): 261-270, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37969049
5.
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
J Am Heart Assoc
; 13(4): e029042, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38362909
6.
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.
Pharmacoecon Open
; 8(1): 19-30, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37606866
7.
Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
Front Pharmacol
; 14: 1195124, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37342587
8.
Resource utilisation and outcomes of people with heart failure in England: a descriptive analysis of linked primary and secondary care data - the PULSE study.
Open Heart
; 10(2)2023 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38070884
9.
Medical Costs of Chronic Kidney Disease and Type 2 Diabetes Among Newly Diagnosed Heart Failure Patients With Reduced, Mildly Reduced, and Preserved Ejection Fraction.
Am J Cardiol
; 198: 72-78, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209530
10.
Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore.
Value Health Reg Issues
; 34: 108-117, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36669346
11.
Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England.
J Cardiovasc Med (Hagerstown)
; 24(10): 758-764, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37577867
12.
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
ESC Heart Fail
; 10(6): 3385-3397, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37670496
13.
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
Eur J Health Econ
; 24(9): 1441-1454, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36463524
14.
Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
J Cardiol
; 81(6): 522-530, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858174
15.
Patient counseling practices in U.S. pharmacies: effects of having pharmacists hand the medication to the patient and state regulations on pharmacist counseling.
J Am Pharm Assoc (2003)
; 51(4): 527-34, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21752776
16.
Medication Use for ADHD and the Risk of Driving Citations and Crashes Among Teenage Drivers: A Population-Based Cohort Study.
J Atten Disord
; 25(11): 1511-1518, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338114
17.
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
ESC Heart Fail
; 7(6): 3910-3918, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32909680
18.
Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.
Pediatrics
; 137(5)2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27244795
19.
High-dose magnesium sulfate infusion protocol for status asthmaticus: a safety and pharmacokinetics cohort study.
Intensive Care Med
; 39(1): 117-22, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23129148
20.
Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.
BMJ
; 345: e4627, 2012 Jul 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-22809800